Business
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company's 2025 achievements and outlining its outlook.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Complex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Bispecific/multispecific antibodies are WuXi Biologics' most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company's revenue and delivers 120%+ YoY growth","length":248,"tagName":"p"}]},{"val":[{"type":"text","content":"Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East","length":124,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":759,"olType":false},{"type":"text","content":"SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company's 2025 achievements and outlining its outlook.","length":246,"tagName":"p"},{"type":"text","content":"Dr. Chen commented, "Through the CRDMO model, we have achieved significant advancements spanning discovery, development, and manufacturing. By executing our 'Follow and Win the Molecule' strategy, world-class quality systems, deep technical capabilities and operational excellence, WuXi Biologics has become the partner of choice for biopharmaceutical innovators and MNCs. With the launch of the CRDMO+ strategy, we will further enable client success by scaling global manufacturing capacity, advancing modality innovation, and accelerating speed and execution."","length":580,"tagName":"p"},{"type":"text","content":"Strong Project Funnel Achieving Record High","length":43,"tagName":"p"},{"type":"text","content":"Building on leading technology, proven execution and expanding global reach, WuXi Biologics added 209 new integrated projects in 2025, increasing the total ...